Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Combination therapy with BRAF and MEK inhibitors for anaplastic thyroid cancer: A report of two cases.

Auris, nasus, larynx - 1 Dec 2024

Yamauchi Mayu, Sakai Akihiro, Ebisumoto Koji, Iijima Hiroaki, Teramura Takanobu, Yamazaki Aritomo, Yanagiya Ryoko, Yamamoto Ai, Ota Yoshiyuki, Ashida Hiroshi, Kobayashi Naoya, Okami Kenji

Abstract excerpt

Anaplastic thyroid cancer (ATC) is an aggressive malignancy with a poor prognosis and limited treatment options. Herein, we report two cases of unresectable ATC treated with a combination of BRAF and MEK inhibitors. The patients were initially treated with other therapies but were switched to BRAF and MEK inhibitors after testing positive for BRAF mutations. This resulted in a partial response, tumor shrinkage,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Imidazoles
Share to Oximes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Pyridones

Share to Pyrimidinones

Share to Sulfonamides

Share to Thyroid Carcinoma, Anaplastic

Share to Thyroid Neoplasms

Share to Vemurafenib

Source

Identifiers

PMID: 39447455
DOI: 10.1016/j.anl.2024.10.002

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Combination therapy with BRAF and MEK inhibitors for anaplastic thyroid cancer: A report of two cases.PMID 39447455Read ↗

Recent advances in anaplastic thyroid cancer management.Semantic proximity Read ↗

Initial Management of BRAF V600E-Variant Anaplastic Thyroid Cancer: The FAST Multidisciplinary Group Consensus Statement.Semantic proximity Read ↗

Mutational Landmarks in Anaplastic Thyroid Cancer: A Perspective of a New Treatment StrategySemantic proximity Read ↗

Advances in the management of anaplastic thyroid carcinoma: transforming a life-threatening condition into a potentially treatable disease.Semantic proximity Read ↗

Case report: Complete response of an anaplastic thyroid carcinoma patient with NRAS Q61R/BRAF D594N mutations to the triplet of dabrafenib, trametinib and PD-1 antibody.Semantic proximity Read ↗

BRAF and MEK inhibition beyond dabrafenib-trametinib in advanced thyroid cancer: a real-world case series.Semantic proximity Read ↗

Evaluating new treatments for anaplastic thyroid cancer.Semantic proximity Read ↗

Efficacy and safety of BRAF/MEK inhibitors in BRAFV600E-mutated anaplastic thyroid cancer: a systematic review and meta-analysis.Semantic proximity Read ↗

Real-World Experience with Targeted Therapy for the Treatment of Anaplastic Thyroid Carcinoma.Semantic proximity Read ↗

Advances in targeted therapy for anaplastic thyroid carcinoma.Semantic proximity Read ↗

Genetic alterations in anaplastic thyroid carcinoma and targeted therapies (Review)Semantic proximity Read ↗

Clinical Development of BRAF plus MEK Inhibitor Combinations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.